|

MRG007 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: ARR-217

Pipeline

Phase 1: 1

Top Sponsors

  • ArriVent BioPharma, Inc.1

Indications

  • Locally Advanced or Metastatic Solid Tumors1
  • Pancreatic Cancer1
  • Colorectal Cancer1
  • Gastric Cancer1
  • Cancer1

Los Angeles, California1 trial

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

ULCA

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.